7 January 2021 in PLOS ONE
The novel coronavirus (COVID-19) is an emergent disease that initially had no historical data to guide scientists on predicting/ forecasting its global or national impact over time. The ability to predict the progress of this pandemic has been crucial for decision making aimed at fighting this pandemic and controlling its spread. In this work we considered four different statistical/time series models that are readily available from the ‘forecast’ package in R. We performed novel applications with these models, forecasting the number of infected cases (confirmed cases and similarly the number of deaths and recovery) along with the corresponding 90% prediction interval to estimate uncertainty around pointwise forecasts. Since the future may not repeat the past for this pandemic, no prediction model is certain. However, any prediction tool with acceptable prediction performance (or prediction error) could still be very useful for public-health planning to handle spread of the pandemic, and could policy decision-making and facilitate transition to normality. These four models were applied to publicly available data of the COVID-19 pandemic for both the USA and Italy. We observed that all models reasonably predicted the future numbers of confirmed cases, deaths, and recoveries of COVID-19. However, for the majority of the analyses, the time series model with autoregressive integrated moving average (ARIMA) and cubic smoothing spline models both had smaller prediction errors and narrower prediction intervals, compared to the Holt and Trigonometric Exponential smoothing state space model with Box-Cox transformation (TBATS) models. Therefore, the former two models were preferable to the latter models. Given similarities in performance of the models in the USA and Italy, the corresponding prediction tools can be applied to other countries grappling with the COVID-19 pandemic, and to any pandemics that can occur in future.
22 June 2022 in JCI Insight
Nontuberculous mycobacteria (NTM) are an increasingly common cause of respiratory infection in people with cystic fibrosis (PwCF). Relative to those with no history of NTM infection (CF-NTM NEG ), PwCF and a history of NTM infection (CF-NTM POS ) are more likely to develop severe lung disease and experience complications over the course of treatment. In other mycobacterial infections (e.g., tuberculosis), an overexuberant immune response causes pathology and compromises organ function; however, since the immune profiles of CF-NTM POS and CF-NTM NEG airways are largely unexplored, it is unknown which, if any, immune responses distinguish these cohorts or concentrate in damaged tissues. Here, we evaluated lung lobe–specific immune profiles of 3 cohorts (CF-NTM POS , CF-NTM NEG , and non-CF adults) and found that CF-NTM POS airways are distinguished by a hyperinflammatory cytokine profile. Importantly, the CF-NTM POS airway immune profile was dominated by B cells, classical macrophages, and the cytokines that support their accumulation. These and other immunological differences between cohorts, including the near absence of NK cells and complement pathway members, were enriched in the most damaged lung lobes. The implications of these findings for our understanding of lung disease in PwCF are discussed, as are how they may inform the development of host-directed therapies to improve NTM disease treatment.
22 September 2020 in Journal of Clinical and Translational Science
Introduction: To identify phenotypes of type 1 diabetes based on glucose curves from continuous glucose-monitoring (CGM) using functional data (FD) analysis to account for longitudinal glucose patterns. We present a reliable prediction model that can accurately predict glycemic levels based on past data collected from the CGM sensor and real-time risk of hypo-/hyperglycemic for individuals with type 1 diabetes. Methods: A longitudinal cohort study of 443 type 1 diabetes patients with CGM data from a completed trial. The FD analysis approach, sparse functional principal components (FPCs) analysis was used to identify phenotypes of type 1 diabetes glycemic variation. We employed a nonstationary stochastic linear mixed-effects model (LME) that accommodates between-patient and within-patient heterogeneity to predict glycemic levels and real-time risk of hypo-/hyperglycemic by creating specific target functions for these excursions. Results: The majority of the variation (73%) in glucose trajectories was explained by the first two FPCs. Higher order variation in the CGM profiles occurred during weeknights, although variation was higher on weekends. The model has low prediction errors and yields accurate predictions for both glucose levels and real-time risk of glycemic excursions. Conclusions: By identifying these distinct longitudinal patterns as phenotypes, interventions can be targeted to optimize type 1 diabetes management for subgroups at the highest risk for compromised long-term outcomes such as cardiac disease or stroke. Further, the estimated change/variability in an individual’s glucose trajectory can be used to establish clinically meaningful and patient-specific thresholds that, when coupled with probabilistic predictive inference, provide a useful medical-monitoring tool.
12 December 2021 in Statistics in Medicine
5 March 2025 in Scientific Reports
The progression of Alzheimer’s disease (AD), a leading cause of dementia worldwide, is known for its variability and complexity, challenging the conventional methods of monitoring and predicting disease trajectories. This study introduces a semiparametric modeling approach to analyze longitudinal cognitive and imaging data. We studied two different outcome variables from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database: the Alzheimer’s Disease Assessment Scale-Cognitive Subscale 13 (ADAS13) scores and ventricular volumes \({(\text{mm}}^{3})\). Unlike traditional linear mixed effects models, semiparametric models do not assume a linear AD progression over time. Semiparametric models offer the advantage of capturing the non-linear features of AD progression, such as cognitive decline and neurodegeneration, represented by changes in ADAS13 scores and ventricular enlargement, respectively. By integrating regression splines and mixed modeling techniques, we provide a nuanced understanding of AD progression that captures the heterogeneity of disease trajectories. Our analysis reveals variations in the timing and degree of cognitive decline and neurodegeneration among AD patients, underlining the need for personalized approaches for monitoring and managing AD. This study’s findings contribute to the modeling of AD progression and offer potential implications for interventions and prognostic assessments in clinical and research settings.